August 23, 2019
Tmunity Announces Participation at Upcoming Investor Conferences
PHILADELPHIA, PA, August 23, 2019 – Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced that Usman “Oz” Azam, MD, President and Chief Executive Officer, and members of the management team plan to participate at two investor conferences in September and October 2019.
Citi’s 14th Annual Biotech Conference
Wednesday, September 4, 2019
Chardan 3rd Annual Genetic Medicines Conference
Monday, October 7, 2019
Podium presentation at 2:00 p.m. ET
New York, NY
About Tmunity Therapeutics
Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases. Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD; Bruce Blazar, MD; Bruce Levine, PhD; Yangbing Zhao, MD, PhD; Jim Riley, PhD; and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine. The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer and two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in East Norriton, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.
# # #
VP, Investor Relations and Corporate Communications
Mike Beyer, Sam Brown Inc.